Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study

Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study

ABSTRACT Later‐line treatment has demonstrated limited survival benefits in patients with metastatic colorectal cancer (mCRC). This retrospective study evaluated the efficacy and safety of a triplet regimen combining metronomic capecitabine, antiangiogenic drugs, and PD‐1 inhibitors in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiong Yang, Yuan‐Yuan Huang, Kai‐Cong Zhang, Qiu‐Sheng Lan, Jie‐Peng Liang, Hui‐Xin Xu, Ya‐Jing Liu, Jing‐Shu Wang, Hui‐Min Liang, He‐Rui Yao, Zhong‐Hua Chu, Hai Hu
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:MedComm
Subjects:
immunotherapy
metastatic colorectal cancer (mCRC)
metronomic chemotherapy
microsatellite stable/mismatch repair proficient (MSS/pMMR)
targeted therapy
Online Access:https://doi.org/10.1002/mco2.70174
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/mco2.70174

Similar Items